Topic:

Clinical Trials

Latest Headlines

Latest Headlines

R.I.P.: Merck and Endocyte yank vintafolide app

Now that the ovarian cancer drug vintafolide has crumbled in Phase III, Merck and its partner Endocyte have pulled their conditional marketing application in Europe and are moving to close down the study.

Boehringer, InterMune wow IPF field with a slate of groundbreaking trial data

The latest download of data on a pair of rival therapies for lethal cases of idiopathic pulmonary fibrosis wowed researchers in the field, producing clear evidence of their ability to slow down the lung disease and offering patients a possible set of game-changing treatments.

Bluebird bio buoyed by news of looming trial data

Shares of Cambridge, MA-based bluebird bio shot up after CEO Nick Leschly noted the looming arrival of early-stage data for its drug LentiGlobin, designed to treat the rare blood disorder beta thalassemia.

Myriad/Crescendo's rheumatoid arthritis test shows viability in new trial

Myriad Genetics paid $270 million for Crescendo Bioscience in February, and now a new study affirms the clinical viability of Crescendo's Vectra DA, a protein-based test designed to assess a patient's rheumatoid arthritis disease progression and activity.

PhIII eye drug failure? Not at all, says an optimistic Gene Signal

At first glance, you might suspect that Gene Signal's Phase III study of its lead drug for a rare eye disease was a roaring success. But if you dig down into its release today, you'll find that the drug flunked its primary endpoint--an inconvenient truth that is dismissed as a mere triviality.

Isis heralds positive PhII diabetes results for a leading antisense drug

Isis says its lead diabetes drug scored a success in a Phase II study, with both doses of ISIS-GCGR spurring a significant drop in blood glucose levels after 13 weeks of therapy in a group of treatment-resistant patients. And the antisense therapy hit its marks on HbA1c without spurring some of the troubling side effects that may hinder rival therapies in the pipeline.

GlaxoSmithKline's blockbuster dreams dashed as darapladib goes 0-for-2 in PhIII

GlaxoSmithKline's last-minute gambit to switch the primary endpoint in its remaining Phase III study of the heart drug darapladib failed to pay off. The pharma giant says that its top cardio prospect flunked the second big trial just as it had the first, leaving the pharma giant staring at a likely writeoff of a one-time megablockbuster hopeful.

Tesaro preps for a Merck showdown after seeing positive PhIII results for rolapitant

Rolapitant, Tesaro's experimental therapy for preventing some nasty side effects of chemo, has hit all the primary and secondary goals, helping boost the company's stock today and leaving it on track to deliver an NDA to the FDA in the next few months.

Pfizer prepares to file for approval with positive PhII MenB data

Last March, Pfizer announced it would file for approval for its meningitis B candidate. Now, it has positive results from a pair of midstage trials for the jab that will keep it on track for expedited approval--and a showdown with Novartis' Bexsero.

AstraZeneca rushes immuno-oncology star into PhIII lung cancer study

Anxious to fight off Pfizer's $106 billion marriage proposal, AstraZeneca's research team has rushed its high-profile immuno-oncology drug into a late-stage test. And they're setting out by targeting non-small cell lung cancer in the first Phase III in the MEDI4736 program.